Tolvaptan, hyponatremia, and heart failure

International Journal of Nephrology and Renovascular Disease

Volumn 4, Issue , 2011, Pages 57-71

  Zmily, Hammam D ^a   Daifallah, Suleiman ^b   Ghali, Jalal K ^c  

^a WAYNE STATE UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c DETROIT MEDICAL CENTER   (United States)

Author keywords

Arginine vasopressin antagonist; Heart failure; Hyponatremia; Tolvaptan

Indexed keywords

ARGIPRESSIN; ARGIPRESSIN DERIVATIVE; CONIVAPTAN; FUROSEMIDE; KETOCONAZOLE; PLACEBO; RIFAMPICIN; TOLVAPTAN;

ACUTE KIDNEY FAILURE; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ASCITES; ASTHENIA; BRAIN HEMORRHAGE; CARDIOPULMONARY INSUFFICIENCY; CONSTIPATION; COUGHING; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; ESOPHAGUS VARICES; FATIGUE; FEVER; GAIT DISORDER; GASTROINTESTINAL HEMORRHAGE; GLUCOSE BLOOD LEVEL; HEADACHE; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART VENTRICLE TACHYCARDIA; HEPATORENAL SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERNATREMIA; HYPERVOLEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; INSOMNIA; IRRITABILITY; KIDNEY FAILURE; LIVER CIRRHOSIS; MALAISE; MONOTHERAPY; MUSCLE WEAKNESS; NAUSEA; NOCTURIA; OSMORECEPTOR; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PNEUMONIA; POLLAKISURIA; POLYDIPSIA; POLYURIA; PRURITUS; PSYCHOSIS; RASH; RESPIRATORY FAILURE; REVIEW; SEPSIS; SIDE EFFECT; SODIUM BLOOD LEVEL; SYNCOPE; TABLET FORMULATION; THIRST; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT CONTRAINDICATION; URIC ACID BLOOD LEVEL; URINARY FREQUENCY; URINARY TRACT INFECTION; UROSEPSIS; VERTIGO; VOMITING; XEROSTOMIA;

EID: 79958776450     PISSN: None     EISSN: 11787058     Source Type: Journal    
DOI: 10.2147/IJNRD.S7032     Document Type: Review

References (46)

1. Ghali JK. Mechanisms, risks, and new treatmen options for hyponatremia. Cardiology. 2008;111:147-157.
2. Renneboog B, Vendemergel X, Manto MN, et al. Mild chronic hyponatremia is associated with falls, unsteadiness and attention deficits. Am J Med. 2006;119:71e1-71e8.
3. Sandhu HS, Gilles E, DeVita MV, et al. Hyponatremia associated with large bone fracture in elderly patients. Int Urol Nephrol. 2009;41: 733-737.
4. Kinsell S, Moran S, Sullivan MO, et al. Hyponatremia independent of osteoporosis is associated with fracture occurrence. Clin J Am Soc Nephrol. 2010;5:275-280.
5. Gankam Kengne F, Andres C, Sattar L, et al. Mild hyponatremia and risk of fracture in the ambulatory elderly. QJM. 2008;101:583-588.
6. Waikar SS, Mount DB, Curhan GC. Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med. 2009;122: 857-865.
7. Wald R, Jaber BL, Price LL, Upadhyay A, Madias NE. Impact of hospital-associated hyponatremia on selected outcomes. Arch Intern Med. 2010;170:294-302.
8. Sajadieh A, Binici Z, Mouridsen MR, et al. Mild hyponatremia carries a poor prognosis in community subjects. Am J Med. 2009;122: 679-686.
9. Gheorghiade M, Abraham WT, Albert NM, et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Optimize-HF Investigators and Coordinators. Eur Heart J. 2007;28:980-988.
10. Ghali JK. Hyponatremia in heart failure: a call for redefinition. Eur Heart J. 2007;28:920-921.
11. Decaux G. Is asymptomatic hyponatremia really asymptomatic? Am J Med. 2006;119(7A):S79-S82.
12. Guyton AC. The body fluids and kidneys. In: Guyton AC, Hall JE, editors. Textbook of Medical Physiology. Philadelphia (PA): WB Saunders Company; 2006:291-414.
13. Oliet SH, Bourque CW. Mechanosensitive channels transducer osmosensitivity in supraoptic neurons. Nature. 1993;364:341-343.
14. Wade CE, Keil LC, Ramsay DJ. Role of volume and osmolality in the control of plasma vasopressin in dehydrated dogs. Neuroendocrinology. 1983;37:349-353.
15. Schrier RW. Water and sodium retention in edematous disorder: role of vasopressin and aldosterone. Am J Med. 2006;119:S47-S53.
16. Schrier RW, Berl T, Anderson RJ. Osmotic and nonosmotic control of vasopressin release. Am J Physiol. 1979;236:F321-F332.
17. Mitchell LD, Barron K, Brody MJ, et al. Two possible actions for circulating angiotensin II in the control of vasopressin release. Peptides. 1982;3:503-507.
18. Thibonnier M, Conarty DM, Preston JA, et al. Molecular pharmacology of human vasopressin receptors. Adv Exp Med Biol. 1998;449:251-276.
19. Ali F, Guglin M, Vaitkevicius P, et al. Therapeutic potential of vasopressin receptor antagonists. Drugs. 2007;67:847-858.
20. Nielsen S, Kwon TH, Christensen BM, et al. Physiology and pathophysiology of renal quaporins. J Am Soc Nephrol. 1999;10:647-663.
21. Tanoue A, Ito S, Honda K, et al. The vasopressin V1B receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. J Clin Invest. 2004;113:302-309.
22. Samsca (tolvaptan) [prescribing Information]. Tokyo, Japan: Otsuka Pharmaceutical Co, Ltd. 2009. http://www.samsca.com/pdf/samscaPI.pdf. Accessed May 2, 2010.
23. Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860-867.
24. Shoaf SE, Wang Z, Bricmont P, et al. Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects. J Clin Pharmacol. 2007;47:1498-1507.
25. Hauptman PJ, Zimmer C, Udelson J, et al. Comparison of two doses and dosing regimens of tolvaptan in congestive heart failure. J Cardiovasc Pharmacol. 2005;46:609-614.
26. Hirano T, Yamamura Y, Nakamura S, et al. Effects of the V2 receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther. 2000;292:288-294.
27. Shoaf SE, Mallikaarjun S. Effect of ketoconazole and grapefruit juice, CYP3A4 inhibitors, on the pharmacokinetics of tolvaptan, a non-peptide vasopressin antagonist. Clin Pharmacol Ther. 2008;83:S57.
28. Mallikaarjun S. Effect of rifampin, CYP3A4 inducer, on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide vasopressin antagonist. Clin Pharmacol Ther. 2008;83:S57.
29. Shoaf SE, Elizari MV, Wang Z, et al. Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias. J Cardiovasc Pharmacol Ther. 2005;10:165-171.
30. Shoaf SE, Bramer SL, Bricmont P, et al. Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide. J Cardiovasc Pharmacol. 2007;50:213-222.
31. Shoaf SE, Wang Z, Mallikaarjun S, et al. Lack of clinically significant interaction between steady state tolvaptan and digoxin in healthy volunteers. Clin Pharmacol Ther. 2004;75:P37.
32. Konstam MA, Gheorghiade M, Burnett JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure, the EVEREST outcome trial. JAMA. 2007;297:1319-1331.
33. Okita K, Sakaida I, Okada M, et al. A multicenter, open-label, doseranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis. J Gastroenterol. 2010;45:979-987.
34. Gheorghiade M, Gottlieb SS, Udelson JE, et al. Vasopressin V2 receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol. 2006;7:1064-1067.
35. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2 receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099-2112.
36. Berl T, Quittnat-Pelletier F, Verbalis J, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol. 2010;21: 705-712.
37. Josiassen RC, Goldman M, Jessani M, et al. Double-blind, placebocontrolled, multicenter trial of a vasopressin V2 receptor antagonist in patients with schizophrenia and hyponatremia. Biol Psychiatry. 2008; 64:1097-1000.
38. Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2 receptor blockade with tolvaptan in patients with chronic heart failure, results from a double-blind, randomized trial. Circulation. 2003;107:2690-2696.
39. Gheorghiade M, Gattis WA, Barbagelata A. Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. Am Heart J. 2003;145:S51-S54.
40. Gheorghiade M, Gattis WA, O'Connor C, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963-1971.
41. Gheorghiade M, Orlandi V, Burnett JC, et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: outcome study with tolvaptan (EVEREST). J Card Fail. 2005;11:260-269.
42. Gheorghiade M, Konstam MA, Burnett JC, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure, the EVEREST clinical status trials. JAMA. 2007;297:1332-1343.
43. Pang PS, Konstam MA, Krasa HB, et al. Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J. 2009;30:2233-2240.
44. Udelson JE, Orlandi C, Ouyang J, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. JACC. 2008;52:1540-1545.
45. Udelson JE, McGrew FA, Flores E, et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. JACC. 2007;49:2151-2159.
46. Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. Vasopressin- 2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006;290:F273-F278.